Indeed, the presence in human serum of a heatstable protein fraction soluble in acid proteinprecipitating agents was recognized as long ago as I892 (Freund) , and this fraction was subsequently studied by Zanetti (I897) , Bywaters (I906, I909), Rimington (1940) and others. An excellent historical account is given by Sonnet (1956) .
Variations-usually increases-in the plasma concentration of seromucoid are found in many conditions. The purpose of this brief review is to outline the principal diagnostic uses to which the estimation of seromucoid has been applied. No (I955) has suggested that the concentration of seromucoid is the resultant of an extremely labile interplay between two groups of nonspecific factors: on the one hand tissue responses associated with inflammation, degeneration or trauma, which raise the seromucoid concentration, and on the other hand hepatic or endocrine insufficiency, which are associated with low concentrations. The seromucoid-enhancing factors usually predominate.
It must be emphasized that the seromucoid fraction, as prepared by treatment of serum with perchloric acid, contains a number of proteins, among which various workers have identified orosomucoid (a,-acid glycoprotein), 3.5S oc,-glycoprotein and haptoglobin, as well as several others (Winzler, I960; de Vaux St. Cyr, I960) . Since the individual components of the seromucoid fraction contain differing amounts of carbohydrate and may vary independently in their concentrations, it follows that estimations based on measurement of the protein content of the fraction will not necessarily agree with those based on measurement of its carbohydrate content. Variations in the carbohydrate/protein ratio have been stated to be of diagnostic value (see below).
It may be expected that specific determination of the individual glycoproteins, for example by immunochemical methods (cf. Gell, I957; Easton, Hardwicke and Whitehead, I962), will in the future provide more useful information than has been obtained by the methods used hitherto.
Diagnosis of Cancer
Some of the most striking increases in plasma seromucoid concentration are found in many types of cancer (Winzler and Smyth, 1948) . In a series of II4 cases studied by Lockey, Anderson and Maclagan (1956) , the highest values were recorded in patients with widely disseminated cancer; results were particularly striking in the lymphomata, while in malignant disease confined to bone very little elevation was found; and Shetlar, Foster, Kelly, Shetlar, Bryan and Everett, 1949) . There remained another group of patients in whom the test failed to detect cancer: these patients either had tumours of border-line malignancy, with little or no invasiveness, or else had small, early tumours of internal organs. In such cases, if other investigations prove unhelpful, repeated estimations of seromucoid at intervals may provide the earliest clue to the diagnosis (Cameron, Campbell and Plenderleith, ig6ia).
Occasionally even patients with advanced cancer may show no rise in seromucoid concentration. This was so with two patients in the terminal stages of gastric cancer, and Cameron and his co-authors suggest that the failure of the seromucoid concentration to increase in these two cases may be attributed to the presence of extensive hepatic metastases. This explanation should be accepted with reserve: in published series (Greenspan, Tepper, Terry and Schoenbach, I952; Greenspan and Dreiling, I953; Greenspan, 1954; Keyser, Payne and Stephens, I962) the great majority of patients with hepatic metastases had elevated concentrations of seromucoid, only a few falling within the normal range. Indeed, some of the highest values found were in this group of patients. Nevertheless, it may well be that a certain minimal amount of normal liver tissue is required to produce elevated concentrations of seromucoid.
Seromucoid estimations can also be used to assess response to treatment, and in prognosis. Thus, Cameron and others found that successful treatment by radiotherapy, or with hormones or cytotoxic agents, is associated with a return of seromucoid concentrations to normal (cf. Keyser, 1954) ; and in patients treated surgically a sustained return of seromucoid concentrations to normal is an indication of adequate resection and a favourable prognosis (Cameron and others, i96ia) .
In interpreting the significance of a raised concentration of seromucoid it is particularly important to bear in mind the influence of infection (see Table) .
Selection of Patients for Endocrine Ablation
In the treatment of advanced cancer of the breast by endocrine ablation, remission is achieved in only a minority of patients, and when the employment of such procedures is considered the patient is usually in a feeble state. Burnett, McAllister and Shields (I963) therefore sought methods to help in the selection of patients likely to benefit from operation. In an investigation of 41 patients who underwent endocrine ablation for advanced cancer of the breast they found that very high concentrations of serum glycoproteins were associated with a poor prognosis. They suggest that patients with serum glycoprotein concentrations above certain limits are unlikely to benefit from endocrine ablation. Four (ig6ib) reported essentially normal values in patients with hepatic cirrhosis, and considerable overlapping of the normal range in patients with infective hepatitis. Keyser and others (I962) confirmed the existence of raised seromucoid concentrations in most patients with obstructive jaundice, and especially in most patients with obstruction due to carcinoma or with secondary deposits of carcinoma in the liver; in agreement with Mandel and his colleagues, only a minority of patients with hepatocellular disease were found to have a lowered seromucoid concentration. Shields, McAllister and Burnett (I963) , who made a similar study, concluded that estimation of the seromucoid concentration was of great value in distinguishing hepatic from post-hepatic jaundice. Indeed, they found the estimation of seromucoid-'tyrosine' more useful in differential diagnosis than the conventional tests, especially in the absence of current extra-hepatic disease.
The estimation of seromucoid would seem, then, to have a place in the differential diagnosis of hepatobiliary disease, provided that the results are interpreted cautiously, with due regard to the many factors that may influence the concentration of this fraction. Because of this limitation it is not to be expected that the estimation will help decisively in more than a minority of cases.
According to Greenspan, 'intraglobulin fractional analysis' by a battery of four determinations seromucoid, 'acid-precipitable globulin turbidity' (a measure of xC2 plus P-globulins), zinc sulphate turbidity and total protein-bound hexose-compares favourably with the cephalin flocculation test, estimation of alkaline phosphatase and other established aids in the differential diagnosis of jaundice (Greenspan, 1956; Greenspan and Dreiling, 1957 Patients with 'psychogenic rheumatism' had normal concentrations (Shetlar, Payne, Bullock, Patrick, Hellbaum and Isbmael, 1953) . In rheumatic fever also the seromucoid concentration is considerably increased when the disease is active, but only slightly increased when it is not (Shetlar, 1958) . In patients with myopathies, motor neurone disease and allied conditions those patients who appeared clinically to be actively wasting showed the highest seromucoid concentrations (Keyser, Jenkins, Lloyd, Pallis and Sanders, 1957) . (This last investigation was undertaken not so much with the object of seeking aids to diagnosis as to obtain evidence for an association between increased glycoprotein concentrations and tissue breakdown (cf. Seibert, Seibert, Atno and Campbell, I947) .)
More recently, a raised seromucoid concentration has been found to be associated with other evidence of clinical activity of the intestinal lesion in patients with regional ileitis or ulcerative colitis (Cooke, Fowler, Cox, Gaddie and Meynell, 1958) . The use of the seromucoid estimation in gastroenterology to detect and obtain an estimate of the degree of activity in new patients, and also to check response to therapy, and in long-term follow-up, is summarized by Fowler and Cooke (I96I) .
Other applications of seromucoid estimation, such as the investigation of renal disease and the diagnosis of myeloma, are described by Varay and Masson (I960). Sonnet (1956) although there did appear to be a higher incidence of c.s.f. mucoprotein in patients with neoplasms of the central nervous system, or with proven occlusive cerebral vascular disease, the finding of mucoprotein in the fluid of patients without neurological disease (in the same frequency and amounts as in the whole group of patients with neurological disease) appeared to limit the value of the investigation.
Bauer (I957) has analysed the perchloric acid-soluble, phosphotungstic acid-precipitable fraction of cerebrospinal fluid and has found that it differs from seromucoid of blood in respect of both carbohydrate content and electrophoretic mobility.
Summary
The clinical applications of seromucoid estimation, especially in the diagnosis of cancer, the selection of patients for endocrine ablation, the differential diagnosis of jaundice, and the assessment of activity in various diseases, are briefly described.
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